Answers are grounded in this paper and cite their sources.
Voriconazole, a new azole antifungal agent, showed potent activity against clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was < 0.03 to 0.5 microgram/ml and the MIC at which 90% of isolates are inhibited was 0.25 microgram/ml. In an experimental model of invasive pulmonary aspergillosis which mimics infection in humans, oral voriconazole at dosages of 30 mg/kg of body weight per day significantly delayed or prevented mortality.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: